05/19/2026
Between December 2025 and April 2026, the trial participant achieved remarkable improvements across all key biomarkers, including a 97% reduction in heart inflammation (Cardiac CRP dropping from 13.58 to 0.33 mg/L), coronary risk cut in half (CHD ratio from 1.4 to 0.7), and reversal of prediabetes status (A1c from 5.7% to 5.5%). Additionally, the participant saw meaningful metabolic and hormonal recovery, with HDL "good" cholesterol rising from 39 to 63 mg/dL and total testosterone increasing 41% from 239 to 339 ng/dL, reflecting a comprehensive transformation from a high-risk profile to optimal recovery. (Trial ending 2026_0930)